/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. OncLive® On Air
  2. S18 Ep29: 𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment
S18 Ep29: 𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

S18 Ep29: 𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

OncLive® On Air · Aug 24, 2026

Experts discuss diagnostics and targeted therapies for MET-altered NSCLC, covering ADCs, TKIs, and managing resistance mechanisms.

Inconsistent MET Amplification Definitions Across Trials Complicate Efficacy Comparisons

Clinical trials for MET-targeted therapies in NSCLC use varying definitions for MET amplification, including different Gene Copy Number (GCN) or MET-CEP7 ratio cutoffs. This inconsistency makes it challenging to compare drug efficacy and apply trial data directly to clinical practice.

S18 Ep29: 𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment thumbnail

S18 Ep29: 𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

OncLive® On Air·3 months ago

Higher Response Rates in MET-High NSCLC Don't Guarantee Longer Survival

In the Luminosity study of Taliso-V for MET-overexpressed NSCLC, patients with high C-MET expression had better response rates than those with intermediate expression. However, this did not translate into a significant improvement in median Progression-Free Survival (PFS) or Overall Survival (OS).

S18 Ep29: 𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment thumbnail

S18 Ep29: 𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

OncLive® On Air·3 months ago

Older TKI Crizotinib Serves as a Tolerability Fallback for MET-Altered NSCLC

Despite newer MET TKIs like capmatinib and tipotinib being available, the older drug crizotinib remains a valuable option for NSCLC patients with MET alterations. It is often better tolerated, making it a practical choice for patients who cannot handle the side effects of newer agents.

S18 Ep29: 𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment thumbnail

S18 Ep29: 𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

OncLive® On Air·3 months ago

Liquid Biopsy (ctDNA) Is an Essential Backup When Tumor Re-Biopsy Fails

In managing progressive NSCLC, re-biopsy of the tumor is ideal but often fails to yield enough tissue. A presented case study shows liquid biopsy (ctDNA) as a critical alternative, successfully identifying resistance mechanisms to inform subsequent treatment choices when tissue is unavailable.

S18 Ep29: 𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment thumbnail

S18 Ep29: 𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

OncLive® On Air·3 months ago

Severe Neuropathy from the ADC TALISO-V Is a Key Barrier to Treatment

The MET-directed antibody-drug conjugate (ADC) TALISO-V causes peripheral sensory neuropathy so frequently and severely that it leads to dose reductions (18%) and treatment discontinuation (12%). The side effect is significant enough that some patients decline the therapy altogether.

S18 Ep29: 𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment thumbnail

S18 Ep29: 𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

OncLive® On Air·3 months ago

Next-Gen MET Inhibitor ABN-401 May Reduce Edema by Avoiding AXL Inhibition

The investigational drug ABN-401 shows a lower incidence of peripheral edema, a common side effect of MET inhibitors. Its higher specificity for MET, avoiding inhibition of the AXL kinase which is implicated in edema, demonstrates a path toward better-tolerated drugs through rational design.

S18 Ep29: 𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment thumbnail

S18 Ep29: 𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

OncLive® On Air·3 months ago